Trials / Completed
CompletedNCT01390870
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged prostate (EP). Adherence with EP therapy will be evaluated. The researchers believe that the majority of participants will report that they are compliant with therapy. The data source is a cross-sectional patient survey administered at one time point.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5ARI or AB or Combination Therapy (5ARI + AB) | 5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2011-07-11
- Last updated
- 2017-05-17
- Results posted
- 2012-03-21
Source: ClinicalTrials.gov record NCT01390870. Inclusion in this directory is not an endorsement.